Krishna Institute of Medical Sciences Limited
₹701.90-₹0.55 (-0.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹24,919 Cr
- P/E
- 87.7x
- EV / EBITDA
- 65.6x
- Revenue
- ₹1,384 Cr
- Net margin
- 19.2%
- ROCE
- 16.7%
Price chart
Technical chartScreen technicals →-3.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -6.2%
- 3M
- -13.1%
- 6M
- +5.4%
- 1Y
- -3.6%
- 5Y
- +202.3%
52-week range
Day change -₹0.55 (-0.1%) from ₹702 to ₹702 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in KIMS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Operating margin of 30.0% exceeds Healthcare median (24.8%)
Concerns1
- Negative free cash flow (₹333 Cr)
Rule-based from financial data. Not advice.
About the company
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers neurology, neurosurgery, psychiatry, and neuro rehabilitation; cardiology, cardiac and vascular surgery, heart transplant, and cardio rehabilitation; and pulmonology, interventional pulmonology, thoracic surgery, and lung transplant.
Read moreShow less
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers neurology, neurosurgery, psychiatry, and neuro rehabilitation; cardiology, cardiac and vascular surgery, heart transplant, and cardio rehabilitation; and pulmonology, interventional pulmonology, thoracic surgery, and lung transplant. It also provides medical and surgical gastroenterology, hepatobiliary pancreatic surgery, liver transplant, and bariatric surgery; ear, nose, throat, and head and neck surgery; and nephrology, urology, andrology, renal transplant, gynecology, urogynecology, IVF and art, fetal medicine, and obstetrics. In addition, the company offers orthopedics, arthroscopic and spine surgery, and ortho rehabilitation; medical surgical and radiation, and BMT and hematology; ophthalmology; dermatology, cosmetology, and plastic and reconstructive surgery; and clinical infectious diseases. Further, it provides imaging and interventional radiology; paediatrics and pediatric sub specialities, and neonatology; maxillo-facial surgery; OT and day care anaesthesia and pain medicine; and pathology, microbiology, and biochemistry. Additionally, the company offers molecular biology and clinical hematology; internal medicine, general surgery, and diabetology and endocrinology; and ICU, CTICU, SICU, NICU, PICU, neuro and ECMO ICU, and post transplant ICU services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 40.0 Cr shares
- ISIN
- INE967H01025
- BSE code
- 543308
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹24,919 Cr
- P/E
- 87.7x
- P/B
- 10.9x
- EV / EBITDA
- 65.6x
- EV / Sales
- 20.6x
- P/S
- 20.4x
- Earnings yield
- 1.1%
- 52-week high
- ₹850.75
- 52-week low
- ₹582.25
Profitability
- Operating margin
- 30.0%
- Net margin
- 19.2%
- EBITDA margin
- 31.4%
- ROE
- 12.6%
- ROCE
- 16.7%
- ROA
- 9.8%
- Dividend payout
- 0.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 5.7%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,384 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 13.3%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.1%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹384 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -0.8%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 28.9%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.2%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹262 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -3.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹6.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 32.3%
Solvency and efficiency
- Current ratio
- 7.01
- Debt / Equity
- 0.17
- Debt / Assets
- 0.14
- Debt / EBITDA
- 0.85
- Interest coverage
- 52.29
- Financial leverage
- 1.28
- CFO / Net profit
- 1.11
- Cash / Market cap
- 1.5%
- Cash per share
- ₹9.20
- Asset turnover
- 0.51
- Fixed asset turnover
- 1.81
- Capital intensity
- 0.55
- Debtor days
- 44 days
- Cash conversion cycle
- 44 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹22 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹963 Cr |
| Sales | Operating profit | ₹421 Cr |
| Operating profit | Interest | ₹28 Cr |
| Operating profit | Depreciation | ₹58 Cr |
| Operating profit | Profit before tax | ₹335 Cr |
| Other income | Profit before tax | ₹68 Cr |
| Profit before tax | Tax and other | ₹100 Cr |
| Profit before tax | Net profit | ₹303 Cr |
Revenue and net profit
Revenue grew 13.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹933 Cr | ₹189 Cr |
| FY2022 | ₹1,143 Cr | ₹278 Cr |
| FY2023 | ₹1,132 Cr | ₹252 Cr |
| FY2024 | ₹1,222 Cr | ₹235 Cr |
| FY2025 | ₹1,384 Cr | ₹303 Cr |
Cash flows
FY2025: ₹294 Cr from operations, -₹333 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹291 Cr | -₹26 Cr |
| FY2022 | ₹284 Cr | -₹91 Cr |
| FY2023 | ₹271 Cr | ₹33 Cr |
| FY2024 | ₹262 Cr | -₹307 Cr |
| FY2025 | ₹294 Cr | -₹333 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,384 Cr+13.3%1Y
- Net profit
- ₹303 Cr+28.9%1Y
- Cash from operations
- ₹294 Cr
- Free cash flow
- -₹333 Cr
- Revenue CAGR, 5Y
- 9.1%
- EBITDA CAGR, 5Y
- 12.5%
- Net profit CAGR, 5Y
- 14.2%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,384 Cr | ₹421 Cr | — | ₹303 Cr | ₹294 Cr | -₹333 Cr | 14.0% | +13.3% | +28.9% |
Monthly returns
Month-by-month returns of KIMS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹3,189 Cr |
| Equity capital | ₹80 Cr |
| Reserves | ₹2,088 Cr |
| Borrowings | ₹708 Cr |
| Other liabilities | ₹313 Cr |
| Assets | ₹3,189 Cr |
| Fixed assets | ₹773 Cr |
| Capital work in progress | ₹530 Cr |
| Investments | ₹1,226 Cr |
| Other assets | ₹660 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
KIMS trades at 87.7x earnings against a peer median of 52.6x (a 67% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Krishna Institute of Medical Sciences LimitedKIMSthis companyP/E ↑ premium | ₹24,919 Cr | 87.7x | 10.9x | 12.6% | 65.6x |
| J.B. Chemicals & Pharmaceuticals LtJBCHEPHARM | ₹29,217 Cr | 41.5x | 7.9x | 18.8% | 32.1x |
| Gland Pharma LimitedGLAND | ₹28,321 Cr | 24.5x | 2.8x | 11.6% | 17.3x |
| Syngene International LimitedSYNGENE | ₹25,375 Cr | 58.0x | 5.5x | 11.1% | 26.5x |
| Pine Labs LimitedPINELABS | ₹24,711 Cr | 442.0x | — | -9.1% | 164.0x |
| Dr. Lal Pathlabs LimitedLALPATHLAB | ₹23,777 Cr | 45.0x | 10.2x | 20.2% | 38.3x |
| Wockhardt LtdWOCKPHARMA | ₹22,539 Cr | 160.0x | 7.8x | -23.5% | -2690.8x |
| PIRAMAL PHARMA LIMITEDPPLPHARMA | ₹22,363 Cr | 31.7x | 2.9x | 5.8% | 27.6x |
| Pfizer Ltd.PFIZER | ₹22,230 Cr | 31.5x | 5.8x | 15.3% | 26.2x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
KIMS since 1 January, against earlier years.
Historical volatility
KIMS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 33.0% |
| FY2022 | 35.0% |
| FY2023 | 32.0% |
| FY2024 | 30.0% |
| FY2025 | 30.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,384 Cr |
| Costs | |
| Interest | ₹28 Cr |
| Expenses | ₹963 Cr |
| Operating profitOperating Profit | ₹421 Cr |
| Other income and charges | |
| Profit before tax | ₹403 Cr |
| Tax | |
| Net profitNet Profit | ₹303 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹3,189 Cr |
| Equity capitalEquity Capital | ₹80 Cr |
| Reserves | ₹2,088 Cr |
| Borrowings | ₹708 Cr |
| Other liabilitiesOther Liabilities | ₹313 Cr |
| AssetsTotal Assets | ₹3,189 Cr |
| Fixed assetsFixed Assets | ₹773 Cr |
| Capital work in progressCWIP | ₹530 Cr |
| Investments | ₹1,226 Cr |
| Other assetsOther Assets | ₹660 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹294 Cr |
| Investing cash flowCash from Investing Activity | -₹627 Cr |
| Financing cash flowCash from Financing Activity | ₹339 Cr |
| Change in cashNet Cash Flow | ₹6 Cr |
Learn while you research
Academy chapters picked for Krishna Institute of Medical Sciences Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 87.7, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read